biopharmaceuticals

Provectus Biopharmaceuticals Highlights Preclinical Evidence of PV-10-Mediated Immune Modulation in Burn Wound Healing; Porcine Study Demonstrates Shift Toward Pro-Regenerative Tissue Environment

KNOXVILLE, Tenn., April 02, 2026 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today highlighted newly…

2 weeks ago

XTL Biopharmaceuticals Announces ADS Ratio Change

March 20, 2026 16:10 ET  | Source: XTL Biopharmaceuticals Ltd. RAMAT GAN, ISRAEL, March 20, 2026 (GLOBE NEWSWIRE) -- XTL…

4 weeks ago

Servier and Day One Biopharmaceuticals announce acquisition to expand Servier’s rare oncology portfolio

Acquisition positions Servier as a leader in pediatric low-grade glioma and expands its pipeline with programs targeting adult and pediatric…

1 month ago

Dr. Falk Pharma and Allianthera (Suzhou) Biopharmaceuticals Forge Strategic Partnership for Novel AhR Agonist Development

Freiburg (Germany), Suzhou (China) and Boston (USA), July 30, 2025:  Dr. Falk Pharma GmbH and Allianthera (Suzhou) Biopharmaceuticals Co., Ltd.…

9 months ago

Provectus Biopharmaceuticals Announces Investor Webinar for 2025 Annual Meeting of Stockholders

KNOXVILLE, Tenn., June 09, 2025 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) announced today that…

10 months ago